论文部分内容阅读
目的:系统评价利多卡因与胺碘酮治疗严重室性心律失常的疗效及安全性。方法:通过电子检索5个数据库,纳入利多卡因与胺碘酮治疗严重室性心律失常的所有随机对照试验,逐个进行质量评价和资料提取,并进行Meta分析。结果:符合纳入标准的文章8篇,2个试验被排除;最后共6个试验包括674例患者符合纳入标准进入本系统评价。Meta分析结果显示:①总有效率:胺碘酮优于利多卡因(P<0.001);②病死率:差异无统计学意义(P>0.05);③药物不良反应发生率:利多卡因低于胺碘酮(P<0.05)。结论:本系统评价显示在治疗严重室性心律失常疗效方面,胺碘酮优于利多卡因;在降低患者病死率两者差异无统计学意义;在药物不良反应发生率方面,胺碘酮高于利多卡因。
Objective: To systematically evaluate the efficacy and safety of lidocaine and amiodarone in the treatment of severe ventricular arrhythmia. METHODS: Five databases were searched electronically to enlist all randomized controlled trials of lidocaine and amiodarone in the treatment of severe ventricular arrhythmias. Quality evaluation and data extraction were performed one by one, and Meta-analysis was performed. Results: Eight articles meeting the inclusion criteria were excluded and two trials were excluded. Finally, a total of 6 trials including 674 patients met the inclusion criteria and were included in this review. Meta analysis showed that: ① The total effective rate: amiodarone was superior to lidocaine (P <0.001); ② fatality rate: the difference was not statistically significant (P> 0.05); ③ adverse drug reactions: lidocaine low Amiodarone (P <0.05). Conclusion: This systematic review shows that amiodarone is superior to lidocaine in the treatment of severe ventricular arrhythmia. There is no significant difference between the two groups in reducing the mortality of patients. In the incidence of adverse drug reactions, amiodarone Lidocaine.